CCNU, etoposide, and prednimustine (CEP) in refractory Hodgkin's disease

A. Santoro, S. Viviani, P. Valagussa, V. Bonfante, G. Bonadonna

Research output: Contribution to journalArticlepeer-review


Starting in February 1980, 58 patients with Hodgkin's disease refractory to both MOPP and ABVD received as third-line chemotherapy a combination of CCNU or lomustine, etoposide, and prednimustine (CEP). Complete response (CR) was achieved in 40% of cases and partial response (PR) in 14%. The median duration of CR was greater than 15 months, and the median survival of complete responders was longer than 24 months. In addition, CEP alternating with ABVD was given to 21 patients refractory to MOPP chemotherapy. In this series, CR was documented in 67% of patients with a median duration of 24+ months and a median survival of 36+ months. Treatment was generally well tolerated, and all acute side effects were reversible. Present findings indicate that CEP is an effective regimen in patients refractory to MOPP and ABVD.

Original languageEnglish
Pages (from-to)23-26
Number of pages4
JournalSeminars in Oncology
Issue number1 SUPPL. 1
Publication statusPublished - 1986

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'CCNU, etoposide, and prednimustine (CEP) in refractory Hodgkin's disease'. Together they form a unique fingerprint.

Cite this